Salubris Biotherapeutics · 1 week ago
Senior Director/Vice President, Preclinical Pharmacology & Toxicology
Salubris Biotherapeutics is seeking a visionary and experienced leader to join our team as Senior Director or Vice President, Preclinical Pharmacology & Toxicology. This foundational leadership role offers the opportunity to further establish and lead the Preclinical Pharmacology, Pharmacometrics, and Toxicology function, driving research programs from lead optimization through IND submission.
BiotechnologyHealth CarePharmaceutical
Responsibilities
Serve as a key strategic leader, partnering with the CSO to shape preclinical development strategy across the portfolio
Drive the strategic vision for advancing programs from late-stage discovery through IND/CTA submission, ensuring alignment with corporate objectives and competitive positioning
Anticipate regulatory and scientific challenges, and proactively develop risk mitigation strategies to accelerate program timelines
Design, manage, and interpret pharmacology, PK/PD, and toxicology studies (GLP/non-GLP) to support program advancement
Oversee CRO partnerships, protocol development, study monitoring, and regulatory documentation to deliver high-quality nonclinical data packages
Lead cross-functional collaboration with Bioanalytical, CMC, and Clinical teams to develop integrated nonclinical safety, translational science and CMC development strategies
Ensure seamless translation of preclinical findings into clinical development plans
Mentor and develop internal team members, building organizational capabilities in disease- and target-relevant efficacy studies, PK/PD/biomarker strategies, and translational approaches across cardiovascular/metabolic and oncology therapeutic areas
Qualification
Required
PhD in Biology, Biochemistry, Biomedical Sciences, Pharmacology, Toxicology, Pharmaceutical Sciences, or related scientific discipline
10+ years of relevant pharmaceutical/biotechnology industry experience, including 5+ years in a leadership capacity within preclinical pharmacology, toxicology, and/or DMPK
Demonstrated ability as program lead to advance programs from lead optimization to IND with complex biologics, such as antibodies, and/or antibody conjugates (ADCs, AOCs)
Deep understanding of in vivo pharmacology and toxicology
Solid working knowledge in bioanalysis, PK/PD, and DMPK. Relevant experience with both biologics and small molecules is a strong plus
Experience delivering high-quality preclinical/nonclinical data packages for drug candidate selection and IND-enabling studies
Preferred
Experience with cardiovascular/metabolic therapeutic area or oncology preferred
Benefits
Competitive compensation package including base salary
Performance bonus
Equity participation
Comprehensive benefits
Company
Salubris Biotherapeutics
SalubrisBio was founded in August 2016 as a subsidiary of the China-based pharmaceutical company Salubris Pharmaceuticals Co. Ltd. (www.salubris.com).
Funding
Current Stage
Early StageTotal Funding
$102MKey Investors
Shenzhen Salubris Pharmaceuticals
2024-04-22Series A· $35M
2023-03-28Corporate Round· $35M
2022-03-07Corporate Round· $32M
Recent News
2025-10-18
2025-05-04
Company data provided by crunchbase